• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Retinal cases & brief reports >LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN)
【24h】

LARGE SILICONE DROPLETS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN)

机译：玻璃体玻璃纤维渣后大的硅胶液滴（Avastin）

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Despite its off-label status, intravitreal bevacizumab is the most commonly used intraocular anti-vascular endothelial growth factor agent. Regulation of compounding pharmacies has recently increased to make compounded Pharmaceuticals safer. Despite these changes, a marked increase in symptomatic, large silicone oil droplets following intravitreal bevacizumab injections was noticed.Methods: Retrospective chart review was performed. Within a single private practice, patients who were noted to have large or symptomatic silicone oil bubbles after an intravitreal injection were reviewed.Results: A recent, dramatic increase in the incidence of large or symptomatic silicone oil droplets was noted, with 23 cases noted in the past 5 months, compared with 1 in the previous decade. Patients frequently noted a circular floater consisting of a dark ring surrounding a bright central area immediately following an injection of intravitreal bevacizumab. All bevacizumab injections were from single-piece insulin syringes. B-scan ultrasonography produced a very characteristic reverberation pattern. No inflammation or visual acuity loss was noted because of the droplets; however, some patients were annoyed enough to consider vitrectomy.Conclusion: Patients should be carefully evaluated for this possibility, and the characteristic symptom of a round floater consisting of a dark ring surrounding a bright center, and the prominent reverberation pattern on B-scan ultrasonography may help increase detection. Changes in consent forms and discussion of this possibility are indicated while investigation into the cause of this increased incidence continues, especially if one is administering bevacizumab via the one-piece insulin syringes commonly used by compound pharmacies.
机译：目的：尽管其非标签状态，但玻璃体内贝伐单抗是最常用的眼内抗血管内皮生长因子剂。复合药房的调节最近增加以使复合药物更安全。尽管有这些变化，但尚未出现术中嗜型贝伐单抗注射术后的症状大型硅油液滴的显着增加。方法：回顾性图表审查。在单一的私人实践中，综述了术中含有大型或有症状的硅油泡的患者进行了审查：结果：近期的大型或症状硅油液滴发病率的显着增加，23例注意到过去5个月，与前十年的1相比。患者经常注意到一个圆形浮渣，包括一个暗环，在注射玻璃体内贝伐单抗后立即围绕着明亮的中心区域。所有贝伐单抗注射都来自单件胰岛素注射器。 B扫描超声检查产生了一个非常特征的混响模式。由于液滴没有注意到炎症或视力损失;然而，一些患者足以考虑玻璃体切除术。结论：应仔细评估患者的这种可能性，以及由围绕明亮中心的暗环组成的圆形浮动的特征症状，以及B扫描超声检查的突出混响模式可能有助于增加检测。同意表格的变化和对这种可能性的讨论，同时调查这种增加的发病率的原因，特别是如果一种通过复合药房常用的单件胰岛素注射器施用Bevacizumab。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号